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DIGITAL IMAGE ANALYSIS FOR TUMOR CELLULARITY 
 
AND GLEASON GRADE TO TUMOR VOLUME ANALYSIS 
 
IN PROSTATE CANCER 
 
SOTIRIS E. CHANIOTAKIS 
 
ABSTRACT 
 
Purpose: This study was undertaken to compare HALO™ software image analysis 
measurements of cellularity with visual estimations from the pathologist and to outline a 
protocol for future experimental determinations of cellularity using HALO™. Secondly, 
this study investigated the clinically challenging prostate cancers of Gleason score 7 by 
analyzing a large database of radical prostatectomy (RP) specimens with regard to their 
Gleason grade composition and percentage tumor volume composition. The importance 
of these values of tumor cellularity, prostate volume, and tumor volume data were 
discussed in terms of future diagnostic endeavors. Finally, this study provided a brief 
background on prostate cancer, prostate cancer epidemiology, digital pathology, and the 
limitations and difficulties in the technological transition to digital pathology. All work 
for this study was done at Dana-Farber Cancer Institute (Boston, MA). 
 
Methods: In the first part of this study, histological slides were acquired by radical 
prostatectomy (RP) and contained 12 tumor foci of varying degrees and sizes. These slides 
were scanned and imported into the HALO™ image analysis software. The tumor foci, 
previously demarcated by a pathologist, were annotated by hand in HALO™. An algorithm 
for image analysis was created by training classifiers to recognize and differentiate between 
epithelial tissue, stromal tissue, glass, and other. This process was 
 
v 
 
 
 
accomplished by classifying 62 regions which were tested for accuracy before becoming 
the components of an algorithm to analyze the entire annotation layer. Each tumor focus 
was analyzed individually, and the results were exported into Microsoft
®
 Excel from 
which relevant data were extracted. Cellularity was calculated by the percentage of 
tumor area that the algorithm characterized as epithelial. Cellularity values derived from 
HALO™ measurements for each tumor focus were compared with the visual estimations 
of cellularity provided by the pathologist using Pearson's correlation analysis. 
 
In the second part of this study, a database of 1386 slides containing tumors with 
Gleason scores between 6 and 9 was compiled from 140 RP cases. The average 
percentages of Gleason grades 3, 4, and 5 in each case were determined. The percentage 
of each slide that was occupied by the tumor was also averaged for each case, yielding 
an average percentage of tumor volume for each case. The average Gleason grade 3, 4, 
or 5 percentage for each case was plotted against the associated average tumor volume 
percentage of that case. The cases of Gleason score 7 (3+4, 4+3) were then isolated and 
plotted in a similar manner. Pearson’s correlation analysis was used to determine the 
degree of linear correlation between the two variables in each plot. 
 
Results: In the first part of this study, a statistically significant positive correlation 
between the cellularity estimations of the pathologist and the HALO™ cellularity 
measurements was found (r = 0.92, p < 0.01, n =12). 
 
In the second part of this study, there was a statistically significant negative 
correlation between average Gleason grade 3 percentage per case and average tumor 
volume percentage per case (r = -0.55, p <0.001, n = 140). There was also a statistically 
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significant positive correlation between average Gleason grade 4 percentage per case and 
average tumor volume percentage per case (r = 0.55, p <0.001, n = 140). After slides 
containing Gleason score 6 (3+3) tumor were removed from the data, a statistically 
significant negative correlation remained between average Gleason grade 3 percentage 
per case and average tumor volume percentage per case (r = -0.51, p <0.001, n = 78), and 
a statistically significant positive correlation remained between average Gleason grade 4 
percentage per case and average tumor volume percentage per case (r = 0.5, p <0.001, n = 
101). A statistically significant relationship between average Gleason grade 5 percentage 
and average tumor volume percentage was not found (r = 0.32, p = 0.14, n = 23). 
Conclusions: In the first part of this study, the strong positive correlation between 
HALO™ cellularity values and visual estimations by the pathologist suggests that image 
analysis may be an effective tool for determining cellularity in digital histological 
images. More research using larger sample sizes is recommended to further validate the 
correlation between algorithm-derived cellularity from HALO™ and visual estimation by 
the pathologist. 
 
In the second part of this study, it appears that the volume of prostate tumors of 
Gleason score 7 may have prognostic power, considering that an increased percentage 
composition of Gleason grade 4 correlated with larger tumor volumes. Because this result 
may have significant clinical implications, further research specifically on tumors of 
Gleason score 7 is suggested to verify this relationship. 
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INTRODUCTION 
 
Background 
 
The Prostate 
 
The prostate gland is located inferior to the bladder and totally encompasses the 
superior portion of the urethra(Figure 1). In its gross appearance, the prostate is often 
described as having the size and shape of a walnut, with its narrow portion facing 
inferiorly and its wider, superior portion adjacent and inferior to the base of the 
bladder.
1,2
Because the superior portion of the rectum lies dorsal to the prostate, the 
rectum is the vector for digital rectal examinations (DRE) of the size, shape, and texture 
of the prostate gland.
2,3
 The size of the normal prostate varies between men of different 
heights and ages. The mean prostate volume is about 25 cubic centimeters (cc).
4,5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.Male genitourinary anatomy.
6
 The diagram shows the main 
structures of the male genitourinary system. Downloaded from National Cancer 
Institute (NCI), https://visualsonline.cancer.gov/details.cfm?imageid=9422. 
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On the cellular level the prostate gland is a tubuloalveolar gland organized into 
secretory acini. These acini are composed of epithelial cells lining a central lumen. The 
epithelium contains two distinct types of cells: basal epithelial cells and glandular epithelial 
cells. The basal cells synthesize the basement membrane of the acini and act as the stem cells 
for the glandular epithelial cells. The glandular epithelial cells are the active secretory cells 
that secrete the components of the prostatic fluid into the prostatic ducts which subsequently 
empty into the prostatic urethra prior to ejaculation.
2,7
In addition to epithelial cells, the 
prostate also contains stromal elements which are important in normal function and in cancer 
metastasis. The stroma consists of fibroblasts, endothelial cells of blood vessels, immune 
cells, extracellular matrix (ECM), and lymph 
 
vessels.
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.Benign prostate with hematoxylin and 
eosin (H&E) stain. This image depicts normal 
prostate tissue in a digital histological slide 
scanned from a database of RP specimens at Dana-
Farber Cancer Institute. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.Malignant prostate with hematoxylin 
and eosin (H&E) stain. This image depicts 
malignant prostate tissue in a digital histological 
slide scanned from a database of RP specimens at 
Dana-Farber Cancer Institute. Note the 
lymphocytic infiltration and the disorganization 
of the glands compared with Figure 2. 
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Embryologically, the prostate develops from a combination of mesoderm and 
endoderm. The prostatic glandular epithelium is derived from the endoderm of the 
urogenital sinus, and the stroma is derived from mesenchyme of the mesodermal 
urogenital sinus. Complex interactions between these layers and with hormones lead to 
the development of the prostate.
8,9
 Morphologically, the stroma is easily distinguishable 
from the glandular elements at high magnifications. The stroma is much less cellular and 
stains eosinophilic (Figures 2 and 3). The stark morphological distinctions between the 
stroma and the epithelium are crucial for the purposes of this experiment. The HALO™ 
image analysis software(Indica Labs, Corrales, NM) relies on morphological distinctions 
and can be trained to distinguish and label stromal tissue and epithelial tissue in a 
digitized histological slide. 
 
Zones of the Prostate 
 
The Peripheral Zone 
 
Most prostate cancer develops in the peripheral zone. Seventy-five percent of 
prostate cancers occur in the peripheral zone compared with 20% in the transition zone. The 
remaining 5% of cancers are referred to as incidental cancers and are non-aggressive and 
relatively clinically insignificant. The peripheral zone is the largest zone and therefore 
contains the majority of prostatic glandular tissue. Histologically, the different zones of the 
prostate are similar in appearance. It is theorized that the disparity in cancer development 
between the zones is due to molecular differences in the zones. Further studies are needed to 
distinguish these molecular differences.
10-13
A digital rectal examination (DRE) allows the 
clinician to palpate the peripheral zone of the prostate and 
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detect abnormalities ranging from increased size to structural irregularities. These 
abnormalities may be indicative of prostate cancer. A DRE is not effective at detecting 
tumors beyond this zone of the prostate.
3,14-16 
The Transition Zone 
 
The transition zone of the prostate is the region immediately adjacent to the 
urethra. Benign prostatic hyperplasia (BPH) typically occurs in this region. 
Approximately 20% of prostate cancers occur in the transition zone; however, transition 
zone cancers are frequently missed in trans-rectal biopsies. Transition zone cancers have 
been shown to have a relatively lower Gleason score (grading system for prostate cancer) 
and a lower biochemical reoccurrence compared with cancers which occur in the 
peripheral zone.
11,13 
The Central Zone 
 
The central zone surrounds the ejaculatory ducts and is histologically similar to 
the tissue of the seminal vesicles and the ejaculatory ducts. Prostate cancers that originate 
in the central zone are said to be more aggressive (indicated by a higher Gleason 
score)but possess less volume.
11,13,17,18 
The Seminal Vesicles 
 
The seminal vesicles are a pair of glands which extend from the superior, 
posterior-lateral aspects of the prostate to the dorsal aspect of the bladder. Similar to 
the prostate, the seminal vesicles synthesize and secrete a portion of the seminal fluid. 
The seminal vesicles are not part of the prostate; however, they are removed in radical 
prostatectomy because of frequent infiltration by malignant cells. Infiltration of the 
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seminal vesicles by prostate cancer is a poor sign with regard to the prognosis of the 
patient.1, 2,19, 20 
 
Function of the Prostate 
 
The prostate gland is a component of the male reproductive system and is 
homologous to the Skene’s glands found in females. The prostate secretes alkaline fluid 
that contributes to two-thirds of the total volume of the seminal fluid. Orgasm triggers the 
contraction of the fibromuscular stromal cells in the prostate which expels the prostatic 
fluid into the prostatic urethra to join with the sperm for ejaculation.
1,2
 The prostatic 
secretions have multiple functions. The alkaline fluid helps to protect the sperm from the 
acidic environment of the vagina. Prostatic fluid contains enzymes such as prostate-
specific antigen (PSA), which decreases the viscosity of the sperm, and other substances 
which increase sperm motility. Loss of the prostate gland is almost always incompatible 
with fertility. Because prostatic secretions comprise such a large percentage of the semen 
volume, radical prostatectomy or any other cause of prostate loss makes normal 
ejaculation near impossible.
1, 2,4,5,21-23 
Benign Prostatic Hyperplasia 
 
Non-malignant growth of the prostate is very common in men over the age of 40. 
It has been estimated that 42% of men ages 51-60, 70% of men ages 61-70, and 90% of 
men ages 81-90 have benign prostatic hyperplasia (BPH). BPH is associated with 
unregulated proliferation of the tissues in the transition zone of the prostate. The etiology 
of BPH is relatively poorly understood. Symptoms typically include difficulty urinating 
because of urethral obstruction, weak urine stream, and loss of bladder control. BPH is 
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distinct from prostate cancer, and it has been shown that the relationship between 
BPH and the risk of developing prostate cancer is unclear.
10,24-26 
Adenocarcinoma of the Prostate 
 
Virtually all cancers of the prostate are adenocarcinoma of either the acinar or 
ductal cells within the prostate. Prostate cancer is the second most common type of 
cancer in American men after skin cancer, and it is the second most deadly cancer behind 
lung cancer. The American Cancer Society estimates that over 164,000 men will be 
diagnosed with prostate cancer in 2018. About 1 man in 9 will be diagnosed with prostate 
cancer in his lifetime; however, only 1 man in 41 will die of prostate cancer. For this 
reason, it is estimated that more that 2.9 million men in the United States who have been 
diagnosed with prostate cancer are still alive. The average age of prostate cancer 
diagnosis is 66 years.
3,27-29 
What Are the Symptoms? 
 
Because prostate cancer is often asymptomatic in the early stages, screening for 
this disease is very crucial for early detection and treatment. Some symptoms which 
may be indicative of prostate cancer are frequent, weak, and/or burning urination, 
erectile dysfunction, decreased ejaculation, painful ejaculation, and blood in the urine 
among others. In later and more aggressive stages, prostate cancer often metastasizes 
first to the lymph nodes and then to the bones.
3,7, 14,15,30 
 
 
 
 
 
 
 
 
6 
 
 
 
What Are the Diagnostic Options? 
 
Prostate Screening 
 
Prostate screening is comprised of regular PSA testing and DRE. PSA is a serine 
protease that is produced by both benign and malignant epithelial cells.
3,25
 PSA has 
been established as a reliable indicator of total prostate volume; however, the correlation 
of PSA with tumor volume is more controversial. Some studies have suggested that 
there is a direct and statistically significant correlation between tumor volume and PSA 
levels. More recent studies, however, suggest that PSA is not a valid marker for tumor 
volume and is only correlated with prostate volume.
23
 Prostate cancer overdetection and 
overtreatment have become a public health problem. PSA screening for prostate cancer 
has recently been recommended against by the United States Preventive Services Task 
Force (USPSTF) for men of all ages. The attitude toward PSA screening has shifted 
rapidly in recent years, and the rates of PSA screening have decreased significantly.
22 
 
DRE comprises the other portion of prostate screening. The physician inserts a 
finger into the anus and palpates the prostate from inside the rectum. The physician can 
detect an enlarged prostate and abnormal lumps on the prostate indicating tumors of the 
peripheral zone. Prostate screening is controversial because of questions about its 
efficacy. There is no clear cutoff about what constitutes normal and abnormal PSA levels. 
Many cancers detected by prostate screening may have been clinically irrelevant; 
however, their detection often leads to overtreatment with serious side effects.
3,21-23,30 
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Biopsy 
 
Patients with elevated serum PSA levels and/or abnormal DRE findings may 
receive a biopsy to view the histological nature of the prostate. Patients who have had 
previous negative biopsies may receive repeat biopsies if there is a continuing suspicion 
of prostate cancer. Trans-rectal ultrasound (TRUS)-guided biopsy is currently the most 
reliable method to accurately sample the prostate. TRUS allows for the visualization and 
targeting of abnormal regions within the prostate, which theoretically permits a more 
targeted biopsy procedure leading to greater prostate cancer detection rates. The accuracy 
of the TRUS biopsy approach has been brought into question with studies reporting 
positive predictive values as low as 6% for the detection of cancer. This is due to the vast 
variability between the sonographic properties of tumors and the fact that many tumors 
are multifocal.
14,17,18,31 
 
Prostate Cancer Treatment: Active Surveillance Versus Radical Prostatectomy 
 
After a diagnosis of prostate cancer has been established by microscopic 
examination by the pathologist, the treatment options vary widely depending on the 
specifics of the case. Active surveillance is an approach used for patients who are low-
risk and most unlikely to develop symptoms related to their prostate cancer. The goal of 
active surveillance is to keep track of the cancer and to identify when more aggressive 
treatments are necessary. With the adoption of PSA screening, the rates of prostate 
cancer diagnoses have increased dramatically, leading often to the detection of cancers 
which are clinically insignificant. This trend leads to overdiagnosis and overtreatment of 
prostate cancer and can greatly reduce the quality of life. Active surveillance is an 
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attempt to minimize the overtreatment of prostate cancer and in recent years has become 
much more popular.
3,22 
 
Radical Prostatectomy 
 
Radical prostatectomy (RP)is a surgical removal of the prostate gland and the 
seminal vesicles including resection of surrounding tissue. RP is often accompanied by 
the removal of both pelvic lymph nodes. This procedure attempts to remove the disease 
entirely while preserving continence and fertility in the patient. RP is most beneficial for 
patients with greater than 10 years of life expectancy, although there is no age limitation 
for this surgery. Patients with prostate cancer deemed to be low-risk often face the 
decision between active surveillance and RP. Studies have shown that men with low-risk 
prostate cancer did not significantly reduce all-cause mortality or death after undergoing 
RP. On the other hand, patients with intermediate risk prostate cancer significantly 
reduced all-cause mortality but not death from RP. High-risk prostate cancer confined to 
the prostate is effectively treated by RP; however, most high-risk cancers have 
metastasized and are not effectively treated by RP alone.
19,20,27,32,33 
What Is the Gleason Grading System? 
 
The Gleason grading system for prostate cancer was established in the 1960s and 
1970s by Dr. Donald F. Gleason and has survived the test of time as an effective way to stage 
prostate cancer. The tissue is assigned two grades (each between 1 and 5) by the pathologist, 
and the sum of the grades leads to a Gleason score between 2 and 10. Grades are determined 
by histopathologic features including tumor size, degree of differentiation, 
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and margin status (Figure 4). Gleason grades are strong prognostic indicators and are the 
 
most widely used staging system for prostate cancer in the United States.
31-34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Gleason's staging system for prostate cancer.
35
 This diagram from the International Society of 
Urological Pathology (ISUP) shows the most up-to-date illustration of the morphological and structural 
differences of Gleason grade 1 through 5. Downloaded from the American Urological Association, 
http://www.auanet.org/education/auauniversity/education-products-and-resources/pathology-for-
urologists/prostate/adenocarcinoma/prostatic-adenocarcinoma-gleason-grading-(modified-grading-by-isup). 
 
 
 
 
 
 
 
10 
 
 
 
Gleason Grade and Prognostic Outcome 
 
Treatment protocols for prostate cancer take into account the Gleason score, PSA 
level and density, cancer volume, and life expectancy of the patient. A patient with a 
Gleason score less than or equal to 6 and a life expectancy less than or equal to 20 years 
usually undergoes active surveillance, which includes PSA testing, DRE, and recurrent 
biopsies. Patients with higher life expectancies may receive treatment ranging from 
radiation therapy to radical prostatectomy. 
 
One of the more difficult questions in prostate cancer research and clinical 
practice is how to treat patients with a Gleason score of 7, which is comprised of Gleason 
grades of either 3+4 or 4+3. The outcomes of patients with a Gleason score of 7 are 
highly heterogeneous. It was found that tumors with Gleason grades of 4+3 were 3 times 
more likely to be lethal compared with 3+4 tumors.
34
 This situation with a Gleason score 
of 7 presents a problem because it is the most commonly assigned score, yet the ideal 
course of action for patients within this group may vary drastically from watchful 
waiting to aggressive therapy and surgical treatment.
31-34
A clear, clinical cut-off point 
which is predicated on the percentage composition of Gleason grades 3 and 4 is needed 
to afford patients the ideal treatment for their particular case. 
 
Prostate Volume and Prostate Tumor Volume 
 
Methods of estimating prostate volume in vivo remain controversial. Prostate 
volume is typically estimated by some form of an ellipsoid or bullet volume calculation, 
where the dimensions for calculation are obtained by TRUS. Some studies have 
demonstrated that TRUS ellipsoid calculations significantly underestimate prostate 
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volume when compared with the actual volume obtained from the pathological 
dimensions. Serum PSA measurements have been shown to correlate with prostate 
weight and to a greater extent with prostate volume.
4, 23,36,37
 PSA is not a reliable 
serum marker for prostate tumor volume. Prostate tumor volume remains challenging 
to accurately determine except post-radical prostatectomy. 
 
Cellularity 
 
Cellularity is defined as the percentage of area of a defined tumor region occupied 
by epithelial tumor cells. Tumor regions, which are outlined by the pathologist post-
radical prostatectomy, are not entirely comprised of tumor cells. Within these tumor 
areas there exist epithelial tumor cells, benign epithelial cells, stromal elements, 
secretions, and artifacts of slide preparation. Prostate cancers vary widely in displayed 
cellularity, and tumor cellularity decreases in response to therapy such as chemotherapy, 
radiation, and hormone therapy. Cellularity is important because it allows for the 
determination of a more relevant tumor volume. Two distinct tumors of the same volume 
but different cellularity may have dissimilar characteristics with regard to clinical 
significance and metabolomic signature. Cellularity is traditionally determined by a 
visual estimation from the pathologist. 
 
Specific Aims 
 
It has recently been hypothesized that quantitative and qualitative metabolic 
signatures obtained from the serum can potentially predict Gleason score and therefore have 
potential prognostic power. Work is being done to identify and verify an array of 
compounds of which the quality and quantity may be indicative of the degree of prostate 
 
12 
 
 
 
cancer (Gleason score). Quantitative metabolic markers, however, are only relevant 
when considered in the context of the volume of the tumor from which they arise. 
 
In the present study, there are two main objectives. First, visual cellularity 
estimations are compared with cellularity measurements using the HALO™ image 
analysis software. This comparison determines if the subjective visual estimations from 
the pathologist are in accordance with the objective digital cellularity measurements, and 
highlights the potential for determining cellularity by digital means in the future. 
Determining cellularity is an important step in determining a clinically relevant tumor 
volume. Secondly, the present study investigates the particularly clinically challenging 
prostate cancers of Gleason score 7, within which clinical outcomes are highly 
heterogeneous. An attempt is made to stratify Gleason score 7 cases by their Gleason 
grade composition and percentage tumor volume composition. A hypothesis that tumor 
volume may be an indirect measure of the amount of Gleason grade 4 tumor within each 
case could give tumor volume a potential prognostic power within cases of Gleason 
score 7. 
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METHODS 
 
Visual and Image Analysis Methods for Cellularity 
 
Slide/Image Preparation. For the comparison of visual and HALO™ cellularity, 
14 slides were chosen from a database containing the slide ID, Gleason score, Gleason 
grade percentage, tumor dimensions, and tumor cellularity (visual estimation from 
pathologist). The database was located at and all work was conducted at Dana-Farber 
Cancer Institute (Boston, MA). The slides were from three different patient cases and 
were selected to have a varying degree of tumor size, cellularity, and Gleason grade 
distribution. All of the slides were obtained from RP, sectioned into quarters, and 
processed with the hematoxylin and eosin (H&E) staining technique. The slides were 
cleaned and loaded into the Vectra™ Intelligent Side Analysis scanner (PerkinElmer, 
Waltham, MA) to create high-definition digital images of the slides. The Vectra™ was 
calibrated, and the scan was executed using the brightfield scanning protocol. The 14 
digital images were then imported in .qptiff format into the HALO™ image analysis 
software. 
 
Image Analysis Procedure. The first step in the analysis of the cellularity of the 
tumor region was to annotate the tumor region on the digital image. This was done by 
demarcating the annotation layer using either the mouse or the surface pen as shown in 
Figure 5. 
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Figure 5. Annotation region of a prostate tumor. This image shows the black permanent marker 
demarcation of the tumor region by the pathologist. Within this boundary, the yellow encircled region is the 
annotation layer created in HALO™. This image is a screenshot of the HALO™ software. 
 
 
 
 
After the area of interest was demarcated, the software was trained to recognize 
epithelial tissue (red), stromal tissue (green), glass (blue), and other (orange) (Figure 6). 
This training was accomplished by classifying 62 tissue regions. Throughout the 
classification process, the real-time tuning feature was used to check the algorithm for 
accuracy (Figure 7). After checking for accuracy, the classification algorithm was 
ready to analyze the entire annotation layer (Figure 8). 
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Classification process. This screenshot from the HALO™ software depicts the classifier training 
process. Demarcated in green is a region identified by the trainer to be stroma. Epithelial tissue is 
demarcated in red. Glass (empty regions) is demarcated in blue. Other (secretions, artifacts, etc.) is 
demarcated in orange. Seven regions have been classified in this example. Many more are required to 
complete an accurate algorithm. 
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Figure 7. Real-time classification tuning. This screenshot from HALO™ depicts the testing for classifier 
accuracy. The movable window at the center of the image reflects the algorithm classifications in real-
time. In the present study, classification regions were trained until the real-time classification tuning 
feature showed that the algorithm was accurately classifying the different regions. 
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Image Analysis Settings. Two tumor foci were excluded from classification and 
analysis because of unclear tumor demarcations. The settings for classification and 
analysis of the remaining images were as follows: 
 
In the classifier menu, classifier resolution was set to 2 microns per pixel (μm/px), 
and minimum object size was set to 0 (μm2). A total of 62 classification annotations were 
made: 31 annotations for the epithelial classification (red), 22 annotations for the stromal 
classification (green), 6 annotations for the other classification (orange), and 3 
annotations for the glass classification (light blue). 
 
In the analysis menu under analysis magnification, image zoom was set to 
 
1.Bright field algorithms required the use of color deconvolution to distinguish between 
 
stains. Under stain selection, RGB optical density (OD) values were calibrated for the 
 
first slide, and these values were used in the analysis of all subsequent slides. Stain 1 
 
(hematoxylin) was calibrated at RGB optical density values of (0.804,1.009,0.303), and 
 
stain 2 (eosin) was calibrated at values of (0.002, 0.411, 0.103). Output image was 
 
selected as cell markup. For nuclei detection, stain 1 nuclear detection weight was set to 
 
1,and stain 2 nuclear detection weight was set to 0. Nuclear contrast threshold was set to 
 
0.517 using slide ID 7 as the calibration image. Minimum nuclear optical density was set 
 
to 0.33. Nuclear size was set to a minimum of 6.800 μm2and a maximum of 571.7 μm2. 
 
Minimum nuclear roundness was set to 0, allowing for the inclusion of elongated and 
 
irregularly shaped nuclei. Nuclear segmentation aggressiveness was set to 0.881, and fill 
 
nuclear holes was set to false. Cell membranes were not of interest in the current study, 
 
and the membrane segmentation feature was not used. Stain 1 was set to have a nuclei 
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positive threshold of 2.5, a cytoplasm positive threshold of 2.5, and a membrane positive 
threshold of 2.5. Stain 2 was set to have a positive nuclei threshold of 0.105, a positive 
cytoplasm threshold of 2.5, and a positive membrane threshold of 2.5. The exclusion 
threshold was set to 0.41, and the exclusion radius was set to 5. Classifier output type 
was set to mask, minimum tissue OD was set to 0.037, tissue edge thickness was set to 0, 
and store object (cell) data was set to true. 
 
Data Analysis. Each tumor focus (1-12) annotation layer was analyzed 
individually to check for proper processing. The results were exported in Microsoft
®
 
Excel format (Microsoft Corporation, Redmond, WA) (Table 1), and the relevant 
information was extracted. Cellularity was calculated using Equation (1): 
 
Cellularity = 
 
 
Area  
epithelial 
Area *100% 
 
classified   
 
(1) 
 
where Areaepithelial is the area of the epithelial tissue and Area classified is the area of the 
annotated layer. Statistical analysis was done using the Microsoft
®
 Excel data analysis 
add-in. A Pearson’s correlation coefficient was computed to measure the strength of the 
linear relationship between the cellularity estimations from the pathologist and the 
HALO™ cellularity measurements (Figure 10). 
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Determination of Gleason Grade Percentage and Tumor Percentage 
 
A database of 1386 slides with tumors having Gleason scores between 6 and 9 
was compiled from 140 RP cases. The database was located at and all experimental work 
was conducted at Dana-Farber Cancer Institute (Boston, MA). The data present for each 
case were the case ID (SurgPath ID), slide ID, percentage tumor volume, Gleason 
grades, Gleason 3 percentage, Gleason 4 percentage, Gleason 5 percentage, and tumor 
dimensions. The percentages of Gleason grades 3, 4, and 5 in each case were averaged 
for all the slides containing tumor. This gave the average Gleason grade percentages of 3, 
4, and 5 (avg Gleason grade 3 percentage, avg Gleason grade 4 percentage, and avg 
Gleason grade 5 percentage, respectively) for each case. The percentage of each tumor 
positive slide composed of tumor was also averaged for each case, yielding an average 
percentage of tumor volume (avg tumor volume percentage) for each case. The average 
Gleason grade percentages of 3, 4, and 5 for each case were plotted against the average 
tumor volume percentage of that case. Pearson's correlation coefficient was computed to 
determine the degree of linear correlation between average Gleason grade (3, 4, or 5) 
percentage and average tumor volume percentage. 
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RESULTS 
 
Results for Image Analysis of Cellularity 
 
The image analysis results for cellularity are shown in Figures 8-10 and Tables 1 
 
and 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Example results of classification. This screenshot from HALO
TM
 displays the classification 
results of an entire annotation layer. Tissue classified as epithelial is shown in red, stromal in green, glass in 
blue, and other in orange. 
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HALO
TM
 Cellularity (%) was calculated using Equation 1. Classified Area refers to the total size of the 
annotation layer (the area of analysis). SurgPath ID is the surgical pathology identification number used 
to identify the case within the database. Focus ID is the identification number assigned to the tumor 
focus. 
 Table 1. Area Calculations, Cellularity Calculations, and Visual Estimates for Classified Foci   
          
         Estimated 
  
Focus 
Classified Epithelial 
Stromal Glass Area Other Area 
HALO
TM 
Cellularity 
 
SurgPath ID Area Area Cellularity by  
ID Area (mm²) (mm²) (mm²) 
      
  
(mm²) (mm²) (%) Pathologist       
         (%) 
 BS-06-F00279 1 3.34 0.64 1.25 0.21 0.74 19.14 40 
          
 BS-06-F00279 2 3.95 1.01 2.75 0.11 0.08 25.54 40 
          
 BS-06-F00279 3 4.65 1.25 2.11 0.32 0.98 26.85 50 
           
BS-06-F00279 4 1.10 0.27 0.72 0.00 0.11 24.36 50 
         
BS-06-N21987 5 4.22 1.10 2.90 0.00 0.22 26.17 60 
 
          
          
 BS-06-F00279 6 4.53 1.65 2.41 0.14 0.33 36.43 65 
          
 BS-05-R28629 7 21.01 8.89 9.54 0.23 2.34 42.30 65 
          
 BS-06-F00279 8 4.92 2.17 1.78 0.35 0.61 44.19 80 
          
 BS-06-N21987 9 24.87 14.23 8.82 0.99 0.82 57.24 85 
          
 BS-06-F00279 10 56.71 24.89 21.36 4.62 5.85 43.88 85 
          
 BS-06-F00279 11 34.46 17.17 11.40 1.67 4.22 49.81 90 
          
 BS-06-F00279 12 26.07 16.83 6.96 1.04 1.25 64.57 90 
2
2
 
 
Table 2. Total Cells and Gleason Grades/Scores for Classified Foci 
 
SurgPath ID Focus ID Total Cells 
Gleason Gleason 
Grades Score    
BS-06-F00279 1 5128 3+3 7 
     
BS-06-F00279 2 6437 3+3 6 
     
BS-06-F00279 3 8809 3+3 6 
     
BS-06-F00279 4 1241 3+3 6 
     
BS-06-N21987 5 9865 4+3 7 
     
BS-06-F00279 6 8870 3+4 7 
     
BS-05-R28629 7 33,520 3+4 7 
     
BS-06-F00279 8 12,676 3+4 7 
     
BS-06-N21987 9 93,488 4+5 9 
     
BS-06-F00279 10 109,186 4+3 7 
     
BS-06-F00279 11 99,110 4+3 7 
     
BS-06-F00279 12 113,124 4+4 8 
     
 
Table 2 shows the total cells counted in the annotated layer (see Figure 9), the Gleason 
grades/scores for each Focus ID, and the SurgPath ID (surgical pathology ID, or case 
ID) from which the focus was selected.  
 
 
Figure 9. Cell counting algorithm application.  
This screenshot from the results of HALO
TM
 
analysis demonstrates the capability of the 
algorithm to segregate and count nuclei. This 
feature can count the approximate number of 
total cells in a demarcated area (Table 2). This 
can be further broken down into the number of 
cells by tissue type. For the purposes of the 
present study, these data are ancillary; 
however, future studies interested in cells per 
area may find this feature effective. 
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Visual vs HALO™ Cellularity 
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Figure 10. Visual cellularity estimations versus HALO
TM
 cellularity measurements. A statistically 
significant positive correlation was found between the two cellularities (r = 0.92, p < 0.001, n = 12). Focus 
ID is the identification number of the tumor focus. Visual estimates are shown in blue, and HALO
TM
 
cellularity measurements are shown in red. Best-fit lines for both visual and HALO
TM
 cellularity values 
display the high degree of positive correlation between the two variables. 
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Results for Gleason Grade Percentages and Tumor Volume Percentages 
 
The results for Gleason grade percentages and tumor volume percentages are 
 
shown in Figures 11-16 and Table 3. 
 
 
 
 
 
 
Table 3. Examples of Average Gleason Grade Percentages and Average Tumor Volume 
Percentages From 10 Prostate Tumor Cases 
 
 Avg Tumor Avg Gleason Avg Gleason Avg Gleason 
SurgPath ID Volume Grade 4 Grade 3 Grade 5 
 Percentage (%) Percentage (%) Percentage (%) Percentage (%) 
05-00588 17.78 56.89 42.56 0.56 
05-02971 31.67 35.00 65.00 0.00 
05-10609 16.67 6.67 93.33 0.00 
05-11141 25.00 15.56 73.33 0.00 
05-14198 51.00 16.00 84.00 0.00 
05-17186 56.82 41.82 56.36 1.82 
05-27335 20.67 8.33 91.67 0.00 
05-32525 38.00 8.00 92.00 0.00 
05-39650 5.00 0.00 100.00 0.00 
05-40822 44.38 75.63 23.75 0.63 
 
Table 3 displays example calculations from 10 cases of prostate tumor. A total of 140 cases were 
analyzed. There were 39 cases of Gleason score 6, 78 cases of Gleason score 7, 0 cases of Gleason 
score 8, and 23 cases of Gleason score 9. Each SurgPath ID represents a unique case containing 
between 10 and 30 slides. Avg tumor volume percentage is the average percentage that the tumor 
occupies across all slides containing tumor within that case. Avg Gleason grade 3, 4, or 5 percentage 
is the average composition of the tumors that is of Gleason grade 3, 4, or 5, respectively. 
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A Pearson’s correlation analysis was conducted on the variables of average 
Gleason grade 3 percentage and average tumor volume percentage (Figure 11). There 
was a significant negative correlation between average Gleason grade 3 percentage and 
average tumor volume percentage(r = -0.55, p <0.001, n = 140). This correlation 
indicates a large association between the two variables: as the average Gleason grade 3 
percentage increases, the average tumor volume percentage decreases. 
 
A Pearson’s correlation analysis was also performed on average Gleason grade 
4 percentage and average tumor volume percentage (Figure 12). In this case, there was 
a significant positive correlation between the two variables (r = 0.55, p <0.001, n = 
140). As the average Gleason grade 4 percentage increases, the average tumor volume 
percentage also increases. 
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Figure 11. Average Gleason grade 3 percentage versus average tumor volume percentage per 
case. These data include all of the 140 cases: 39 cases of Gleason score 6 (100% Gleason grade 3), 
78 cases of Gleason score 7 (3+4 or 4+3), and 23 cases of Gleason score 9 (4+5).A statistically 
significant negative correlation was found between the two variables (r = -0.55, p < 0.001, n = 
140). The distributions of average tumor volume percentage per case and average Gleason grade 3 
percentage per case are shown above and to the right of the plot, respectively. The shaded light blue 
region around the best-fit line is a 95% confidence interval. Terms: gleason_3_percent = average 
Gleason grade 3 percentage per case; pearsonr = Pearson’s correlation coefficient; p = probability 
value (p-value). 
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Figure 12. Average Gleason grade 4 percentage versus average tumor volume percentage per case. 
These data include all of the 140 cases: 39 cases of Gleason score 6 (100% Gleason grade 3), 78 cases of 
Gleason score 7 (3+4 or 4+3), and 23 cases of Gleason score 9 (4+5).A statistically significant positive 
correlation was found between the two variables (r = 0.55, p < 0.001, n = 140). The distributions of 
average tumor volume percentage per case and average Gleason grade 4 percentage per case are shown 
above and to the right of the plot, respectively. The shaded light blue region around the best-fit line is a 
95% confidence interval. Terms: gleason_4_percent = average Gleason grade 4 percentage per case; 
pearsonr = Pearson’s correlation coefficient; p = probability value (p-value). 
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After the removal from the data of slides containing Gleason score 6 tumors, a 
Pearson's correlation analysis was carried out again on the variables of average 
Gleason grade 3 percentage and average tumor volume percentage (Figure 13). There 
was a significant negative correlation between the two variables (r = -0.51, p <0.001, n 
= 78). The association between these variables shows some decrease after removal of 
Gleason score 6 (100% Gleason grade 3) slides. 
 
A Pearson’s correlation analysis was also conducted on average Gleason grade 4 
percentage and average tumor volume percentage after the removal of Gleason score 6 
data points (Figure 14). A significant positive correlation was found between the two 
variables (r = 0.5, p <0.001, n = 101). This association reflects some decrease after 
removal of Gleason score 6 data. 
 
Finally, a Pearson’s correlation analysis was conducted on average Gleason grade 
5 percentage and average tumor volume percentage among cases of Gleason score 9 
(4+5) (Figure 15). A significant correlation was not found between the two variables (r = 
0.32, p =0.14, n = 23). Although not statistically significant, the Pearson’s correlation 
coefficient suggests a medium strength of association between average Gleason grade 5 
percentage and average tumor volume percentage among cases of Gleason score 9 (4+5). 
 
The distributions of average Gleason grade 3 percentage and average Gleason 
grade 4 percentage are displayed in Figure 16. 
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Figure 13. Average Gleason grade 3 percentage versus average tumor volume percentage 
per case for cases of Gleason score 7 only (100% Gleason grade 3 has been  
removed).These data include 78 cases of Gleason score 7 (3+4 or 4+3). A statistically 
significant negative correlation was found between the two variables (r = -0.51, p < 0.001, n =  
78). The distributions of average tumor volume percentage per case and average Gleason grade  
3 percentage per case are shown above and to the right of the plot, respectively. The shaded 
light blue region around the best-fit line is a 95% confidence interval. Terms: 
gleason_3_percent = average Gleason grade 3 percentage per case; pearsonr = Pearson’s  
correlation coefficient; p = probability value (p-value). 
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Figure 14. Average Gleason grade 4 percentage versus average tumor volume percentage 
per case for cases of Gleason score 7 (4+3, 3+4) and Gleason score 9 (4+5).These data include 
78 cases of Gleason score 7 (3+4 or 4+3) and 23 cases of Gleason score 9 (4+5). A statistically 
significant positive correlation was found between the two variables (r = 0.5, p < 0.001, n = 101). 
The distributions of average tumor volume percentage per case and average Gleason grade 4 
percentage per case are shown above and to the right of the plot, respectively. The shaded light 
blue region around the best-fit line is a 95% confidence interval. Terms: gleason_4_percent = 
average Gleason grade 4 percentage per case; pearsonr = Pearson’s correlation coefficient; p = 
probability value (p-value). 
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Figure 15. Average Gleason grade 5 percentage versus average tumor volume percentage 
per case for 23 cases of Gleason score 9 (4+5). No statistically significant relationship was found 
between the two variables (r = 0.32, p = 0.14, n = 23).The distributions of average tumor volume 
percentage per case and average Gleason grade 5 percentage per case are shown above and to the 
right of the plot, respectively. The shaded light blue region around the best-fit line is a 95% 
confidence interval. Terms: gleason_5_percent = average Gleason grade 5 percentage per case; 
pearsonr = Pearson’s correlation coefficient; p = probability value (p-value). 
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Figure 16. Distributions of average Gleason grade 3 and 4 percentages within prostate tumors of Gleason score 7. The figure shows 
that most of the cases are of Gleason grade distribution 3+4. A large fraction of the cases analyzed are comprised of average Gleason grade 3 
percentage between 80% and 99% and average Gleason grade 4 percentage between 1% and 20%. 
 
 
 
DISCUSSION 
 
The diagnosis of clinically relevant prostate cancer in the least invasive manner 
possible requires both the knowledge of what is clinically relevant and the ability to 
detect clinical relevance in a noninvasive manner. Serum metabolomic signatures of 
patients with varying degrees of prostate cancer (Gleason grades and scores)and varying 
tumor volumes are attainable by big data analysis. A prostate cancer patient with a 
certain quantitative metabolomic profile must have that profile normalized by his prostate 
volume and tumor volume. Depending on the ratio of epithelium to stroma within the 
tumor, the metabolomic profile can vary. As a result, cellularity is important. Cellularity 
allows for the calculation of a more accurate and relevant tumor volume. 
 
In the first part of the present study, the results of machine-based algorithms 
trained to identify certain tissue types were compared with the visual estimations of the 
pathologist with regard to cellularity (Figure 10). Given the strength and significance of 
the correlation between the visual estimations and the HALO™ analysis (r = 0.92, p < 
0.01), further studies should be undertaken with larger sample sizes. 
 
The number of samples (n = 12) in this study was very small; however, with the 
required infrastructure in place, this would not be a difficult experiment to expand. The 
main difficulties in this experiment were related to software and hardware infrastructure. 
Acquiring tumor samples from the prostate and having a pathologist score them for 
cellularity are relatively feasible for most clinical research centers. In contrast, the 
hardware and software infrastructure required to scan histological slides, digitally 
manipulate them, and analyze them is complex. Scanning slides takes a considerable 
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amount of time, and scanners are expensive. The drive space and computing power 
required to store and manipulate these large images are expensive and limiting. Despite 
these challenges, further analysis with a larger sample size is recommended. 
 
In addition, an accurate classification and analysis algorithm should be trained by 
a licensed pathologist with expertise in differentiating tissue types. For the present study, 
training and algorithm formation was done by an individual (Sotiris E. Chaniotakis) who 
has graduate-level education in histology but no prostate-specific expertise. This 
represents a significant limitation of this experiment. A preferable situation would have a 
pathologist who trains and saves separate algorithms for different presentations of 
prostate cancer; for example, a separate algorithm for Gleason grades 3+4, 4+3, and 4+5. 
This would allow for an individual without histological expertise to apply these 
algorithms and achieve accurate results. It is possible that because of the lack of 
expertise of the algorithm trainer in the present study, the results might be slightly 
different with a more knowledgeable trainer. However, even between experts in prostate 
histology, there are issues with subjectivity and variation in cellularity estimates, and 
different pathologists are expected to produce non-uniform estimations. Algorithm-based 
classification and analysis protocols can act to reduce this subjectivity to a large degree, 
even though some variance remains between algorithms trained by different people. 
 
Other limitations to the continuation of this study include the presence of unclear 
and rough tumor demarcations on the slides. In this study, many of the RP slides in the 
database were not clear and required a certain degree of additional interpretation by the 
individual conducting the digital analysis. Certain outlines with discontinued or unclear 
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lines needed some judgment in the annotation of the tumor region. This error source was 
significantly reduced by selecting slides with clear tumor demarcations. However, this 
problem may pose a future challenge when dealing with large quantities of RP 
specimens. 
 
The calculation of tumor cellularity ideally gives the percentage of malignant 
cells within the tumor region. In the present study, all epithelial cells within the annotated 
tumor region were assumed to be malignant. This is not the case in reality. Within a given 
prostate tumor there exist a certain number of epithelial cells which are benign. In the 
present experiment, no method was applied to differentiate between malignant and 
benign epithelial cells within the tumor region. The only classification distinctions were 
epithelial, stromal, glass, and other. This classification might have led to an 
overestimation of tumor cellularity by counting benign epithelial cells as malignant. 
Using morphology-based algorithms to distinguish between malignant and benign 
epithelial cells on a large scale may be possible. This requires a detailed study of the 
morphological differences and an incorporation of these differences into the algorithm by 
classifier training. Because morphological differences between malignant and benign 
epithelial cells are most likely found in the details at the nuclear and cytoplasmic level, 
very high-resolution images would be required to allow these differences to be 
incorporated into the algorithm. 
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Figure 17. The “big picture” for the future of non-invasive prostate cancer diagnosis. From a database 
of RP specimens with associated metabolomic data, values for tumor volume, tumor cellularity, prostate 
volume, and Gleason grades can be obtained. If metabolomic profiles can be associated with Gleason 
grades, then metabolomic profiles adopt the prognostic power of the Gleason grading system. If a 
corrected tumor volume, or corrected relative tumor volume (it is unclear at this point which of the two is 
more relevant), can be correlated to Gleason grade, then volume may also possess prognostic power. 
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If relationships can be drawn between Gleason grades, relative tumor volumes, 
and metabolomic profiles (Figure 17), it may be possible to make inferences about 
Gleason grades from metabolomic profiles and/or tumor volumes. Theoretically, this 
gives the potential for both metabolomic profiles and tumor volumes to have prognostic 
power with regard to prostate cancer. 
 
In the second part of the present study, tumors of Gleason score 7 were of 
primary interest because there is much variability in prognosis among patients within this 
category. Perhaps somewhere within this Gleason score lies a clinically relevant cutoff 
for treatment options, particularly as it has been demonstrated that tumors comprised of 
Gleason grades 3+4 (primarily Gleason grade 3) are not equivalent to tumors of Gleason 
grades 4+3 (primarily Gleason grade 4). The experiment in the present study investigated 
the relationship between the percentage of the slide comprised of tumor volume, 
percentage of Gleason grade 4, and percentage of Gleason grade 3within cases of 
Gleason score 7. The results clearly showed that the higher the percentage composition 
of Gleason grade 4, the higher the percentage of tumor volume (r = 0.55, p < 0.001). This 
relationship intuitively makes sense because more aggressive tumors theoretically expand 
faster and to a greater extent. If a reliable correlation between percentage of Gleason 
grade 4 and percentage of tumor volume can be established, it may be possible to better 
differentiate Gleason score 7 tumors and to use tumor volume in the identification 
process of tumors requiring more aggressive therapies. 
 
Nevertheless, there are significant limitations in this experiment which must be 
addressed. First of all, this experiment was looking at the relationship between tumor 
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percentage of the slide and the percentage of the tumor that was Gleason grade 3 or 
Gleason grade 4. The only reliable conclusions from this experiment were that as the 
percentage of the slide becomes increasingly occupied by tumor, more of that tumor 
region is comprised of Gleason grade 4, and within tumors of Gleason score 7, the 
opposite relationship exists with Gleason grade 3. Extrapolation of these results leads to 
the conclusion that within Gleason score 7 tumors, the volume of the tumor may be an 
indicator of the Gleason grade distribution and may also be a factor of prognostic power. 
This experiment, however, considered only the slides with tumor present from each 
case, assuming that these slides made up the entire prostate when, in fact, they 
represented a fraction. Prostates obtained by RP vary in volume, number of slices, and 
size of each slice. 
 
In order to confirm the relationship suggested in the present work, a future study 
should investigate the association between the total amount of each Gleason grade per 
case and the total tumor volume per case. Three dimensional measurements (in the form 
of length x width x height) are available for each case. Applying these measurements to 
a volume estimator, such as the ellipsoid or bullet calculator, may give an accurate 
estimation of prostate volume. From the calculated prostate volume, the approximate 
volume of each slide can be obtained by dividing the total volume of the prostate by the 
number of slides. This is an approximate value because each slide contains different 
amounts of the prostate and all slices of the prostate are often not submitted for 
histological preparation. The percentage of tumor on each slide multiplied by the volume 
of the slide gives the amount of tumor for that slide, and the sum of these values across 
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the number of slides results in the total tumor volume. The percentage of a given Gleason 
grade multiplied by the amount of tumor on the slide indicates the amount of that 
Gleason grade per slide. The sum of these values gives the total amount of the Gleason 
grade of interest. An analysis of the amount of Gleason grade 3, 4, or 5, together with the 
total tumor volume, would provide more information on the relationship between 
Gleason grade and tumor volume. 
 
The theoretical limit of artificially intelligent algorithms in tissue analysis appears 
endless. If the data and the manpower/expertise to build a good classifier are available, 
artificially intelligent image analysis should be faster, more consistent, and more accurate 
than human analysis. The feasibility of achieving this goal in the short term seems difficult. 
The limiting factor in the implementation of artificial intelligence (AI)-based pathology is 
the infrastructure required to manage and manipulate the large amount of image data, and the 
expert manpower required to create good classifiers. Although the algorithms are relatively 
small and manageable after they are designed, the actual data sets required to create these 
effective algorithms are cumbersome. As computing power becomes more affordable and 
accessible, the feasibility of implementing AI-based pathology analysis is likely to increase. 
This will require increased collaboration across research centers in order to accumulate large 
data sets for training and analysis.
38-41 
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